LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

3.59 -0.28

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.52

Max

3.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 51.415
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+260.11% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-70M 840M
Ankstesnė atidarymo kaina	3.87
Ankstesnė uždarymo kaina	3.59

Naujienos nuotaikos

By Acuity

34%

66%

69 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

0.7658 / N/A Palaikymas ir pasipriešinimas

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-17 23:53; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-17 23:50; UTC

Rinkos pokalbiai

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-17 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-17 23:36; UTC

Rinkos pokalbiai

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

2026-05-17 23:07; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Transactions Part of Group's Capital Reallocation Strategy

2026-05-17 23:06; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Share Sale Agreements Entered With Singland Properties

2026-05-17 23:05; UTC

Įsigijimai, susijungimai, perėmimai

UOB: Divestments' Aggregate Consideration of S$299M in Cash

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Fund Stake Acquisition via Internal Resources

2026-05-17 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire Stake for $389 Million

2026-05-17 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

2026-05-16 16:27; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

2026-05-16 15:26; UTC

Įsigijimai, susijungimai, perėmimai

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

2026-05-16 08:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

260.11% į viršų

12 mėnesių prognozė

Vidutinis 13 USD 260.11%

Aukščiausias 16 USD

Žemiausias 11 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

69 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.